Apothecary Pharma Recalls Compounded Tirzepatide Injections Due to Sterility Concerns

Apothecary Pharma LLC has initiated a Class II recall of 22 vials of its compounded tirzepatide injection (18 mg/mL, 4 mL multi-dose vials) and one vial of NAD+ injection (200 mg/mL, 6 mL multi-dose vial) across the U.S. due to a lack of assurance of sterility. The FDA had previously issued a warning letter to the company in December 2025 citing deficiencies in sterile drug product manufacturing. Patients are advised to stop using affected lots and contact their prescriber.